61587-90-4

Basic information

• Product Name: 1H-Benzimidazole,5-methyl-6-nitro-(9CI)
• Synonyms: 1H-Benzimidazole,5-methyl-6-nitro-(9CI);5-Methyl-6-nitro-1H-benzo[d]iMidazole;5-methyl-6-nitro-1H-Benzimidazole
• CAS NO: 61587-90-4
• Molecular Formula: C₈H₇N₃O₂
• Molecular Weight: 177.16008
• Product Categories: BENZIMIDAZOLE
• Mol File: 61587-90-4.mol
• Article Data: 5

Chemical Properties

• Melting Point: 197 °C(Solv: water (7732-18-5); ethanol (64-17-5))
• Boiling Point: 458.8±25.0 °C(Predicted)
• Appearance: /
• Density: 1.437±0.06 g/cm3(Predicted)
• PKA: 11.52±0.30(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole,5-methyl-6-nitro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole,5-methyl-6-nitro-(9CI)(61587-90-4)
• EPA Substance Registry System: 1H-Benzimidazole,5-methyl-6-nitro-(9CI)(61587-90-4)

Safety Data

• Hazardous Substances Data: 61587-90-4(Hazardous Substances Data)

Usage

General Description

1H-Benzimidazole,5-methyl-6-nitro-(9CI) is a chemical compound with the molecular formula C8H7N3O2. It is a derivative of benzimidazole, which is a heterocyclic compound containing a benzene ring fused to an imidazole ring. The compound is characterized by the presence of a methyl group at the 5-position and a nitro group at the 6-position of the benzene ring. It is commonly used in pharmaceutical and chemical research and has potential applications in the development of drugs and agrochemicals. The compound's properties and potential uses make it a topic of interest for scientists and researchers in various fields.

Upstream product

• 64-18-6 formic acid 
• 65958-37-4 4-methyl-5-nitrobenzene-1,2-diamine 
• 614-97-1 5-methylbenzimidazole 
• 7664-93-9 sulfuric acid 
• 7697-37-2 nitric acid 
• 5267-27-6 5-amino-2,4-dinitrotoluene 
• 537-92-8 3-Methylacetanilide 

Downstream Products

• 177843-72-0 5-methyl-1H-benzo[d]imidazol-6-amine 

Relevant articles and documents

BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS

The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Src kinase inhibitor compounds

Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.